Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBAPFG)

Drug Name
Brinzolamide Drug Info
Synonyms
Azopt; Birnzolamide; Alcon brand of brinzolamide; Allphar brand of brinzolamide; Brinzolamide [USAN]; AL 4862; AL04862; BZ1; AL-4862; Azopt (TN); Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
Therapeutic ClassAntiglaucomic Agents
Cross-matching ID
PubChem CID
68844
ChEBI ID
CHEMBL220491
CAS Number
CAS 138890-62-7
TTD Drug ID
D01MUR
INTEDE Drug ID
DR0229

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.31 0.00e+0 93/133 (69.92%) COX6C;CYC1;ATP6V1D;...
Spliceosome 2.02 5.71e-3 101/150 (67.33%) LSM5;PUF60;PRPF4;...
DNA replication 1.99 5.71e-3 34/36 (94.44%) RFC5;SSBP1;MCM3;...
Protein export 1.99 4.28e-3 17/23 (73.91%) SRPRA;SEC61B;SRP9;...
Thermogenesis 1.80 1.83e-2 173/232 (74.57%) GNAS;COX6C;CYC1;...
Steroid biosynthesis 1.72 2.85e-2 19/20 (95%) SOAT1;SC5D;SQLE;...
Huntington disease 1.71 2.85e-2 233/306 (76.14%) POLR2I;KIF5C;COX6C;...
Primary bile acid biosynthesis 1.70 2.92e-2 15/17 (88.24%) AMACR;CYP46A1;SLC27A5;...
D-Glutamine and D-glutamate metabolism 1.65 4.69e-2 5/5 (100%) GLS;GLS2;DGLUCY;...
Homologous recombination 1.64 4.45e-2 35/41 (85.37%) RAD51C;SSBP1;RPA3;...
Signaling pathways regulating pluripotency of stem cell... -1.62 4.05e-2 110/143 (76.92%) LIF;INHBE;MAPK11;...
Melanoma -1.64 3.60e-2 68/72 (94.44%) DDB2;EGF;EGFR;...
Gastric cancer -1.64 3.58e-2 122/149 (81.88%) GAB1;LRP6;FGF9;...
MAPK signaling pathway -1.64 3.61e-2 272/294 (92.52%) RPS6KA5;MAPK11;TAB1;...
Toxoplasmosis -1.64 3.74e-2 103/112 (91.96%) TGFB1;GNAI2;HSPA8;...
Pertussis -1.65 3.57e-2 64/76 (84.21%) TNF;MAPK13;IRAK1;...
FoxO signaling pathway -1.65 3.55e-2 118/131 (90.08%) PLK3;SOS1;SKP2;...
Type II diabetes mellitus -1.65 3.69e-2 42/46 (91.3%) TNF;SOCS3;SLC2A2;...
Chemokine signaling pathway -1.66 3.56e-2 163/192 (84.9%) CCL11;CXCL8;SOS1;...
Th1 and Th2 cell differentiation -1.66 3.60e-2 80/92 (86.96%) NFATC3;ZAP70;IFNG;...
Hepatocellular carcinoma -1.66 3.76e-2 135/168 (80.36%) TCF7;GADD45G;SMARCD3;...
Allograft rejection -1.68 3.41e-2 32/38 (84.21%) HLA-F;HLA-G;IFNG;...
p53 signaling pathway -1.69 3.58e-2 63/73 (86.3%) IGFBP3;BBC3;DDB2;...
Cytokine-cytokine receptor interaction -1.69 3.56e-2 246/295 (83.39%) IL21R;GDF5;GDF9;...
Breast cancer -1.70 3.60e-2 119/147 (80.95%) DDB2;EGF;EGFR;...
Leukocyte transendothelial migration -1.70 3.81e-2 90/114 (78.95%) ROCK2;PLCG1;MSN;...
Porphyrin and chlorophyll metabolism -1.70 4.05e-2 23/43 (53.49%) GUSB;ALAS2;UGT2B17;...
Staphylococcus aureus infection -1.70 4.14e-2 72/95 (75.79%) ITGB2;FCGR2B;ICAM1;...
Galactose metabolism -1.71 4.23e-2 26/31 (83.87%) UGP2;GALT;HK1;...
Sulfur metabolism -1.73 4.03e-2 9/10 (90%) MPST;TST;ETHE1;...
Fluid shear stress and atherosclerosis -1.75 4.14e-2 123/139 (88.49%) TNF;MAPK13;EDN1;...
Endometrial cancer -1.76 4.14e-2 56/58 (96.55%) CTNNA1;DDB2;EGF;...
Lipid and atherosclerosis -1.78 4.14e-2 190/215 (88.37%) ROCK2;PPP3CC;PLCG1;...
Intestinal immune network for IgA production -1.87 1.18e-2 38/48 (79.17%) AICDA;ICOS;IL15;...
TNF signaling pathway -1.92 2.30e-3 103/112 (91.96%) CASP8;CREB3L1;FADD;...
Asthma -1.93 2.76e-3 25/31 (80.65%) FCER1A;IL9;TNF;...
Systemic lupus erythematosus -1.95 0.00e+0 45/135 (33.33%) CD86;C3;HLA-DOB;...
Basal cell carcinoma -2.13 0.00e+0 41/63 (65.08%) FZD1;DDB2;PTCH1;...
Viral protein interaction with cytokine and cytokine re... -2.16 0.00e+0 84/100 (84%) CXCR5;CCL17;TNFRSF14;...
Mineral absorption -2.53 0.00e+0 48/60 (80%) ATP1B2;ATP2B1;SLC5A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 4uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H